Abstract:Newborn screening (NBS) plays a significant role in reducing the risk of birth defects. NBS in China began in the early 1980s. Under the protection of laws and regulations and the leadership of the national health administration, approved screening centers in public hospitals took the responsibility for publicity, screening, diagnosis, treatment, follow-up and management of birth defects. As of 2022, 31 provinces (autonomous regions and municipalities directly under the central government) have carried out NBS for phenylketonuria, congenital hypothyroidism, and hearing loss, 23 provinces have carried out screening for glucose-6-phosphate dehydrogenase (with a screening rate of 89.24%), and 24 provinces have carried out screening for congenital adrenal cortical hyperplasia (91.45% screening rate). Over the past four decades, screening techniques have evolved from bacterial inhibition, fluorescence analysis, and tandem mass spectrometry for the detection of biochemical markers to genetic testing, which has greatly contributed to the expansion of the types of diseases screened for. The combined use of metabolomics and genomics is currently being explored. Effective management and rigorous quality control of NBS are prerequisites for improving the quality and ensuring the accuracy of screening. The Quality Management System for Newborn Screening System Network (QMS-NBS), established by the National Center for Clinical Laboratories, covers all screening centers and related blood collection agencies. The operation of the QMS-NBS allows the quality and performance of screening to be transparent and measurable, ensuring the quality and efficiency of screening. This article provides an overview of the history of NBS, especially the evolution of policies for the NBS in China, the construction of screening institutions, the number of newborns screened, the incidence rates of screened diseases, the changes in screening technology, the expansion of new diseases screened for, and the quality control of NBS. Overall, the progress in NBS in China has not only benefited from the development and standardization at the technological level, but also benefited from the construction of policies, regulations and ethics.

Newborn Screening for Inborn Errors of Metabolism in Mainland China: 30 Years of Experience.

Newborn Screening in Zhejiang, China

Neonatal screening for congenital hypothyroidism and phenylketonuria in China

[Retrospective Study on Neonatal Screening for Congenital Hypothyroidism and Phenylketonuria in China in the Past 22 Years].

[Screening for neonatal inborn errors of metabolism by electrospray ionization-tandem mass spectrometry and follow-up].

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening.

Screening for congenital hypothyroidism in neonates of Zhejiang Province during 1999-2004]

Pitfalls in the Management of Phenylketonuria in China

[Screening for Phenylketonuria and Congenital Hypothyroidism in 5.8 Million Neonates in China].

Screening for phenylketonuria in 726,998 neonates in Zhejiang Province]

Problems and reflection on the screening and diagnosis for disease of newborn

Progress of newborn screening in China

Study of the Administrative Approach of Newborns Screening in Zhejiang Province

[Screening for Fatty Acid Oxidation Disorders of Newborns in Zhejiang Province:Prevalence, Outcome and Follow-Up].

Neonatal Screening for Inborn Errors of Metabolism in Shanghai

Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Incidence of Inborn Errors of Metabolism Detected by Tandem Mass Spectrometry in China: A Census of over Seven Million Newborns Between 2016 and 2017.

Screening of 1.17 million newborns for inborn errors of metabolism using tandem mass spectrometry in Shanghai, China: A 19-year report

Newborn Screening for Inherited Metabolic Diseases Using Tandem Mass Spectrometry in China: Outcome and Cost-Utility Analysis